Medicine availability must be measured at the pharmacy window
Stock figures matter, but public accountability should extend to whether patients receive their full treatment when they need it.
Pharmacists and clinical experts argue medicine accessibility should be evaluated at the point of prescription fulfillment rather than relying solely on stock figures. Colleen Aldous, a professor of clinical medicine, stresses patients deserve their prescribed treatment in correct quantities when needed. South Africa must measure medicine supply against this patient-focused endpoint, in addition to procurement and distribution metrics.
In September 2026, the National Department of Health aimed to maintain public trust in medicine supply by explaining that alterations in appearance or packaging do not automatically signal a shortage. This clarification matters, as patients shouldn't lose confidence in treatment simply because of visual changes. Generic medicines contain identical active ingredients and regulatory requirements as their branded counterparts.
Interchangeable products permit uninterrupted treatment when a specific supplier's product is unavailable. A manufacturer change alone does not indicate a denied treatment, but the health department's reassurance may be overlooking a critical issue.
The department's reassurance raises another question: how often do supply management measures ensure patients receive their full prescribed treatment? While stock may exist at various points in the supply chain, a patient at one facility may still leave without their prescribed medication. These scenarios can occur simultaneously, as availability at one point does not guarantee access at another.
Redistribution and therapeutic alternatives, such as procuring from different facilities or using alternative treatments, are crucial components of an effective pharmaceutical system. Their effectiveness should be measured by their impact on patient access. An interchangeably generic dispensing counts as successful, while a clinically agreed treatment change should be recorded separately, with information on whether it was due to supply constraints.
Existing monitoring tools, such as the Stock Visibility System and National Surveillance Centre, are valuable assets for tracking medicine availability and providing early warnings of potential supply issues. However, monitoring tools alone are insufficient; public reporting of patient-access indicators is essential. The question to be answered is: of the patients presenting with a valid prescription due at a visit, how many receive the full clinically appropriate supply on that visit?
Approved interchangeable generics should be counted as successful dispensing, while clinical changes in treatment regimens should be recorded separately, with information on whether they were prompted by supply constraints. This patient-access metric would provide a more comprehensive understanding of medicine availability, helping to identify and address potential gaps in treatment access.
Written by urgent.news from Daily Maverick's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.